Cause Of Rare Blood Clots Linked With AstraZeneca, Johnson & Johnson Covid Vaccines Found: Study
NDTV
COVID-19 Vaccine Study: Both the AstraZeneca and Johnson & Johnson vaccines use an adenovirus to carry spike proteins from the coronavirus into people to trigger a protective immune response.
Scientists have found a possible trigger behind the extremely rare blood clots linked to AstraZeneca and Johnson & Johnson COVID-19 vaccines, an advance that may help design new and improved preventives against the viral disease.
An international team of researchers investigated vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS), a life-threatening condition seen in a very small number of people after receiving the adenovirus vaccines.
"The mechanism which results in this condition, termed vaccine-induced immune thrombotic thrombocytopenia (VITT), was unknown," said corresponding author of the study Abhishek Singharoy, from Arizona State University, US.
The researchers at Arizona and Cardiff University in the UK worked with AstraZeneca to analyse whether the ultra-rare side effect could be linked to the viral vector which is used in many vaccines, including those from Oxford/AstraZeneca and Johnson & Johnson.
